NCT07337577Recruiting
Targeted Artificial Intelligence Language mOdel Recommendations for Heart Failure (TAILOR-HF)
Large Language Model-Generated Messages to Improve Guideline-Directed Medical Therapy in Heart Failure
Source: ClinicalTrials.gov · Last updated 31 Aug 2026
Brief summary (registry, in English)
This study is an investigator-initiated, cluster-randomized implementation trial evaluating a large language model (LLM)-based clinical decision support (CDS) tool designed to improve guideline-directed medical therapy (GDMT) for adult patients with heart failure seen in outpatient cardiology clinics at Mass General Brigham. For eligible heart failure encounters, the CDS tool reviews existing electronic health record (EHR) data, including diagnoses, medications, vital signs, laboratory results, and recent notes, and generates brief, clinician-facing messages suggesting opportunities to initiate or optimize GDMT and highlighting relevant safety considerations. Messages are delivered to cardiology providers via Epic InBasket and/or institutional email prior to scheduled visits. The tool is advisory only and cannot place orders or change medications automatically; all treatment decisions remain at the discretion of the treating clinician and patient. Cardiology providers are assigned at the provider/clinic level to early implementation of the CDS tool versus usual care (no messages) during the initial phase. The primary outcome is GDMT optimization within 30 days of an index visit. Secondary outcomes include feasibility of CDS generation and delivery and a 30-day safety composite (e.g., heart failure hospitalization, acute kidney injury, hyperkalemia, hypotension or bradyarrhythmia plausibly related to GDMT).
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 500 (estimated)
- First submitted
- 12 Jan 2026
- Start date
- Aug 2026
- Primary completion date
- Sept 2027
- Lead sponsor
- Brigham and Women's Hospital
- Diseases
- Heart failure
- NCT number
- NCT07337577
What you commit to
- Study type: Interventional
- Planned participants: 500
- From Aug 2026 to the primary completion date, Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Heart rate \<50 beats per minute on the most recent recorded measurement
- Known cardiac amyloidosis or hypertrophic cardiomyopathy
- History of heart transplant or presence of a left ventricular assist device
- Severe aortic stenosis, severe aortic insufficiency, or severe mitral stenosis on the most recent echocardiogram
- Encounter occurs in an adult congenital heart disease clinic
Lab values
- eGFR \<20 mL/min/1.73 m² on the most recent laboratory assessment
Other
- Systolic blood pressure \<90 mmHg on the most recent recorded measurement
Who the study is looking for
- Age ≥18 years
- Scheduled outpatient visit with a participating cardiology provider in an MGB outpatient cardiology clinic
- At least one prior cardiology clinic visit in the MGB system within the past 2 years
- Diagnosis of heart failure by ICD code within the past 2 years
- Heart failure diagnosis supported by at least one of the following:
- Current or recent use of a loop diuretic
- Left ventricular ejection fraction ≤40% on the most recent echocardiogram
- Explicit documentation of heart failure diagnosis or heart failure signs/symptoms in a prior cardiology note
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mass General Brigham Coordinator of this site? Confirm its status | Boston | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.